ASCO’s 2018 theme, “Delivering Discoveries: Expanding the Reach of Precision Medicine,” certainly played out this year from the plenary podium to abstracts to posters and the exhibit hall. Each of the Blue Fin Group team who attended exceeded our daily fitness steps in the search for knowledge, both to bring to our colleagues, and to our clients.
We heard the promising outcomes of IO therapy as a single agent and the anticipation of greater results with combinations across tumor types. We saw promising data where until now treatment has been limited at best. Companion diagnostics ongoing development will provide greater insights for custom treatment to optimize patient outcomes. And we continue to hear the impact of patient engagement (active decision making and feedback on treatment) on improved care – with patients at the core. With evolving standard of care the need for clinical trial participation rings its percussive bell. As a clinical trial patient shared, “It’s important for people to know clinical trials are always an option and not just something to consider when all other options have been exhausted.”
It’s always great seeing old friends and meeting new ones. Exciting times lies ahead. I look forward to collaborating in delivering discoveries.